{"nct_id":"NCT01449461","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)","status":"COMPLETED","status_verified_date":"2021-07","start_date":"2011-09-20","start_date_type":"ACTUAL","primary_completion_date":"2015-11-16","primary_completion_date_type":"ACTUAL","completion_date":"2020-02-18","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["TAK"]}